NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.